- Home
- EML vs FENC Comparison
EML vs FENC Comparison
Compare EML & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | FENC |
|---|---|---|
| Founded | 1858 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 258.5M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | EML | FENC |
|---|---|---|
| Price | $19.87 | $7.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 12.1K | ★ 154.3K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | $38,790,000.00 |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | $75.22 |
| P/E Ratio | $19.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.49 | $4.68 |
| 52 Week High | $30.03 | $9.92 |
Technical Indicators
Market Signals| Indicator | EML | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 45.98 |
| Support Level | $19.28 | $7.50 |
| Resistance Level | $20.86 | $8.00 |
| Average True Range (ATR) | 0.63 | 0.29 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 67.16 | 43.08 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.